Mingqian Feng Selected Research

Glypicans

1/2022	Highly Potent Immunotoxins Targeting the Membrane-distal N-lobe of GPC3 for Immunotherapy of Hepatocellular Carcinoma.
1/2021	Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells.
1/2020	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
10/2019	A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice.
1/2019	Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks.
5/2017	Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy.
6/2015	Glypican-3 targeted human heavy chain antibody as a drug carrier for hepatocellular carcinoma therapy.
3/2015	Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
8/2014	Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
1/2014	Glypican-3 antibodies: a new therapeutic target for liver cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mingqian Feng Research Topics

Disease

17	Neoplasms (Cancer) 01/2022 - 10/2010
11	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 10/2010
8	Liver Neoplasms (Liver Cancer) 01/2022 - 10/2010
4	Mesothelioma 04/2013 - 01/2011
2	Ovarian Neoplasms (Ovarian Cancer) 05/2011 - 01/2011
2	Neoplasm Metastasis (Metastasis) 05/2011 - 01/2011
1	Hypoxia (Hypoxemia) 01/2021
1	Inflammation (Inflammations) 10/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Severe Acute Respiratory Syndrome 01/2019
1	Second Primary Neoplasms (Neoplasms, Second) 01/2019
1	Coronavirus Infections 01/2019
1	Type I Syndactyly 04/2013
1	Pancreatic Neoplasms (Pancreatic Cancer) 05/2011
1	Adenocarcinoma of Lung 05/2011
1	Malignant Mesothelioma 01/2011
1	Cholangiocarcinoma 10/2010

Drug/Important Bio-Agent (IBA)

12	GlypicansIBA 01/2022 - 05/2011
7	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2011
6	Immunotoxins (Immunotoxin)IBA 01/2022 - 01/2011
5	MesothelinIBA 04/2013 - 10/2010
4	AntibodiesIBA 06/2015 - 01/2011
3	AntigensIBA 01/2020 - 01/2011
2	Immunoconjugates (Immunoconjugate)IBA 01/2022 - 01/2011
2	Cadherins (E-Cadherin)IBA 01/2021 - 01/2011
2	Biological ProductsIBA 10/2020 - 01/2014
2	LuciferasesIBA 01/2020 - 03/2011
2	Single-Domain AntibodiesIBA 04/2013 - 03/2013
2	Monoclonal AntibodiesIBA 04/2013 - 01/2011
2	Peptides (Polypeptides)IBA 04/2013 - 01/2011
2	EpitopesIBA 04/2013 - 01/2011
1	roblitinibIBA 01/2022
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2022
1	Bispecific AntibodiesIBA 01/2022
1	Angiogenesis InhibitorsIBA 01/2022
1	Immunoglobulin IsotypesIBA 07/2021
1	Immune Checkpoint ProteinsIBA 07/2021
1	VimentinIBA 01/2021
1	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 01/2021
1	Chimeric Antigen ReceptorsIBA 01/2020
1	PerforinIBA 01/2020
1	Granzymes (Granzyme)IBA 01/2020
1	Cysteine (L-Cysteine)FDA Link 10/2019
1	CateninsIBA 10/2019
1	human ERBB2 proteinIBA 01/2019
1	Viral AntigensIBA 01/2019
1	Drug CarriersIBA 06/2015
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 03/2015
1	Heparitin Sulfate (Heparan Sulfate)IBA 08/2014
1	Proteoglycans (Proteoglycan)IBA 08/2014
1	Complement System Proteins (Complement)IBA 04/2013
1	Glycoproteins (Glycoprotein)IBA 05/2011
1	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA 05/2011
1	Immunoglobulin G (IgG)IBA 05/2011
1	RNA Polymerase II (RNA Polymerase B)IBA 03/2011
1	Bacterial ToxinsIBA 01/2011
1	Pharmaceutical PreparationsIBA 01/2011
1	MucinsIBA 01/2011

Therapy/Procedure

14	Therapeutics 01/2022 - 10/2010
2	Immunotherapy 01/2022 - 10/2010
1	Drug Therapy (Chemotherapy) 01/2020
1	Injections 01/2020
1	Intraperitoneal Injections 01/2020
1	Radiotherapy 01/2020
1	Orthoptics (Orthoptic) 01/2020